ArticleMaternal & child nutrition2025
Cardiometabolic Markers Associated With Altered Fetal Growth in Mediterranean Cohort.
Article in Maternal & child nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiometabolic disturbances in pregnancy appear to be associated with inappropriate fetal growth, but evidence from uncomplicated pregnancies is still scarce and, due to varied findings, inconclusive. Moreover, most studies focus on specific markers, often measured at a single gestational time-point. We aimed to assess the associations between maternal cardiometabolic markers, measured in early and late pregnancy, and neonatal size in a Mediterranean cohort of healthy women. Longitudinally, we analyzed 264 mother-neonate pairs. Maternal metabolic markers (glucose, insulin resistance, triglycerides, total cholesterol, HDL-c, LDL-c, and blood pressure (BP)) were assessed in the first (T1) and third (T3) trimesters. Birthweight (g) and head circumference (HC, cm) were assessed in the newborns. Small (SGA, < 10th percentile) and large (LGA, > 90th percentile) for-gestational-age were the primary outcomes. Multivariable-adjusted linear and logistic regressions were performed. Overall, based on weight and HC at birth, there were 10.5% and 6.4% SGA infants, while 8.1% and 16.7% were LGA, respectively. After adjustments for confounders, maternal T1 triglycerides were positively associated with birthweight (β:74.81 g per 1-SD increment, p = 0.006), and higher T1 LDL-c levels increased the risk of LGA newborns (OR:1.64 g per 1-SD increment, p = 0.046). T3 diastolic-BP was inversely associated with birthweight (β:-86.19 g per 1-SD increment; p = 0.010) and HC (β:-0.30 g per 1-SD increment; p = 0.008). High diastolic-BP (≥ 75th percentile, 77 mmHg) was also linked to a higher risk of SGA newborns for both weight (OR:3.54, p = 0.022) and HC (OR:2.56 g per 1-SD increment, p = 0.025). In conclusions, elevated maternal lipids in early pregnancy and diastolic BP in late pregnancy adversely impact offspring birth size, highlighting the importance of incorporating metabolic monitoring into routine prenatal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.